2019 International Congress » Neuropharmacology

1:45pm-3:15pm

Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease

D. Khatri (Pune, India)

1:45pm-3:15pm

Apomorphine induced hemolytic anemia: A case report and literature review

F. Hajiakhoundi, M. Motamed, M. Rohani, G. Shahidi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm

Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients

R. Borgohain, T. Sd, T. Syed, V. Kutala, R. Kandadai, S. Meka, S. Tandra (Hyderabad, India)

1:45pm-3:15pm

Behavioural aspect of transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by Ropinirole alginate nanocomposite

F. Naz, R. X, YHS. Siddique (Aligarh, India)

1:45pm-3:15pm

Benefit and Weakness with botulinum toxin: time course and relationship.

P. Kassavetis, K. Alter, C. Lungu, B. Karp (Bathesda, MD, USA)

1:45pm-3:15pm

Chlorogenic acid attenuates the MPTP induced apoptosis in Parkinson’s disease mouse model through pAkt signaling pathway

S. Singh, S. Singh (Varanasi, India)

1:45pm-3:15pm

Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy

D. Gugulothu, R. Nagapuri, DK. Khatri (Pune, India)

1:45pm-3:15pm

Differential enhancement of ERK, PKA and Ca2+ signaling in direct and indirect striatal neurons of Parkinsonian mice

LL. Mariani, S. Longueville, JA. Girault, D. Hervé, N. Gervasi (Paris, France)

1:45pm-3:15pm

Effect of dopamine D2-receptor antagonist and basal ganglia neuromodulation on neuronal activity in the cerebral motor area and cerebellar dentate nucleus

K. Schwabe, A. Abdulbaki, S. Helgers, J. Krauss, M. Alam (Hannover, Germany)

1:45pm-3:15pm

Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease

N. Miyaue, M. Nomoto, H. Yabe, Y. Yamanishi, S. Tada, R. Ando, M. Kubo, M. Nagai (Ehime, Japan)

1:45pm-3:15pm

Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study

I. Straka, M. Minár, M. škorvánek, M. Grofik, J. Benetin, P. Valkovič (Bratislava, Slovakia)

1:45pm-3:15pm

Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats

CA. Pisanò, A. Brugnoli, S. Novello, C. Caccia, C. Keywood, E. Melloni, G. Padoani, S. Vailati, M. Morari (Ferrara, Italy)

1:45pm-3:15pm

Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease

S. Neo, A. Wong, HL. Ng, W. Li, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)

1:45pm-3:15pm

Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.

H. Bouchaoui, L. Mahoney-Sanchez, A. Jonneaux, F. Gouel, M. Dutheil, JC. Devedjian, G. Garçon, D. Devos (Lille, France)

1:45pm-3:15pm

Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: Roles of Nrf2-ARE signaling pathway

XF. Guo, T. Wang, J. Huang, N. Xiong, C. Han, K. Ma, Y. Xia, F. Wan, JJ. Hu, SJ. Yin, L. Kou, YD. Sun, JW. Wu (Wuhan, China)

1:45pm-3:15pm

In vivo and In vitro study of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats : A therapeutic potential drug for Alzheimer’s disease

P. Kumar, N. Baquer (New Delhi, India)

1:45pm-3:15pm

LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset

A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm

Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment

B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

1:45pm-3:15pm

Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease

E. Bezard, Q. Li, E. Pioli, A. Crossman (Bordeaux, France)

1:45pm-3:15pm

Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

1:45pm-3:15pm

Quercetin Regulates Cadmium Induced Motor Dysfunction in Depletion of Dopamine and its Metabolites at Synapse

R. Gupta, RK. Shukla, AB. Pant, VK. Khanna (Lucknow, India)

1:45pm-3:15pm

Results of community pharmacist-led structured medication reviews in Parkinson’s Disease

N. Oonk, P. Oude Avenhuis, K. Movig, K. Koehorst-Ter Huurne, WH. Nijmeijer, M. van Kesteren-Biegstraaten, J. Vd Palen, L. Dorresteijn (Enschede, Netherlands)

1:45pm-3:15pm

Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

1:45pm-3:15pm

Safinamide reduces membrane excitability and synaptic transmission of striatal spiny projection neurons in a rat model of Parkinson’s disease

A. Tozzi, M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

1:45pm-3:15pm

Sudden alopecia secondary to levodopa treatment

N. Garcia Alvarado, N. López Ariztegui, MI. Morales Casado, JC. Segundo Rodríguez, C. Schoendorff Ortega, R. Almansa Castillo, JA. Perez Matos, A. ávila Fernández, C. Marsal Alonso (Toledo, Spain)

1:45pm-3:15pm

The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients

N. Durmaz çelik, M. Kuzu Kumcu, S. Bostan, E. Yiğit Tekkanat, S. özkan (Eskisehir, Turkey)

1:45pm-3:15pm

The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm

Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine

RWK. Borgemeester, GFH. Diercks, T. van Laar (Groningen, Netherlands)